Evaluation of 47Sc-labeled PDGFRβ-targeting Affibody for Pancreatic Cancer Imaging and Therapy
Overview
This study investigates a novel 47Sc-labeled affibody targeting PDGFRβ for SPECT imaging and radiotherapy in pancreatic cancer. The affibody demonstrated high affinity and specificity for PDGFRβ expressed in cancer-associated fibroblasts, enabling precise tumor visualization and potential therapeutic application.
Background
Pancreatic cancer is highly malignant with poor prognosis due to its invasiveness, recurrence, and treatment resistance. The tumor microenvironment, particularly cancer-associated fibroblasts (CAFs), plays a critical role in tumor progression and resistance. PDGFRβ is a biomarker highly expressed on CAFs in pancreatic tumors, making it a promising target for molecular imaging and therapy. The radionuclide 47Sc offers favorable properties for theranostic applications, combining SPECT imaging and radiotherapy.
Data Highlights
47Sc was produced via neutron irradiation of 46Ca and purified using DGA resin chromatography. The ZPDGFRβ affibody was genetically engineered and expressed in E. coli. Radiolabeling with 47Sc allowed for stable complex formation suitable for imaging and therapeutic use. Preclinical imaging demonstrated high-contrast visualization of PDGFRβ-expressing tumors in mouse xenograft models.
Key Findings
PDGFRβ is highly expressed on CAFs in pancreatic cancer, serving as an effective molecular target.
The affibody targeting PDGFRβ was optimized for enhanced affinity and specificity through amino acid sequence modification and dimerization.
47Sc was successfully produced and purified, forming stable complexes with the affibody via DOTA chelation.
47Sc-labeled affibody enabled high-contrast SPECT imaging of pancreatic tumor xenografts in mice.
The radionuclide 47Sc’s physical properties support its dual use in imaging and radiotherapy, facilitating theranostic applications.
Clinical Implications
Targeting PDGFRβ with a 47Sc-labeled affibody offers a promising approach for noninvasive detection and treatment of pancreatic cancer by visualizing CAFs within the tumor microenvironment. This theranostic strategy could improve patient stratification and optimize therapeutic dosing, potentially overcoming limitations of current imaging and treatment modalities.
Conclusion
The 47Sc-labeled PDGFRβ-targeting affibody represents a novel theranostic agent with potential to enhance diagnosis and radiotherapy of pancreatic cancer by specifically targeting the tumor microenvironment. Further clinical development is warranted to validate its efficacy and safety.
Related Resources & Content
Lindborg et al. 2020 -- Affibody targeting PDGFRβ with high affinity and specificity
Wang et al. 2022 -- Radiolabeled affibodies for PET imaging in pancreatic cancer
Smith et al. 2019 -- Theranostic radionuclides in nuclear medicine
